- In May 2021, Octapharma USA's investigational new drug (IND) application for a phase three clinical trial on the efficacy and safety of Octagam 10 percent [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression was authorized by the US Food and Drug Administration (FDA).
Frequently Asked Questions
The market is segmented based on Segmentation, By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain‐Barré Syndrome, Others), Product (IgA, IgG, IgM, IgE, IgD), Mode of Delivery (Intravenous, Subcutaneous) – Industry Trends and Forecast to 2032
.
The Global Immunoglobulins Market size was valued at USD 16.06 USD Billion in 2024.
The Global Immunoglobulins Market is projected to grow at a CAGR of 7.05% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
